Edition:
United Kingdom

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

24.51USD
22 May 2018
Change (% chg)

$-0.06 (-0.24%)
Prev Close
$24.57
Open
$24.61
Day's High
$25.10
Day's Low
$24.51
Volume
3,358
Avg. Vol
144,621
52-wk High
$34.98
52-wk Low
$13.06

Chart for

About

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development... (more)

Overall

Beta: --
Market Cap(Mil.): $984.19
Shares Outstanding(Mil.): 38.92
Dividend: --
Yield (%): --

Financials

  CTMX.OQ Industry Sector
P/E (TTM): -- 222.84 32.59
EPS (TTM): -2.02 -- --
ROI: -33.98 -7.75 12.60
ROE: -123.20 -10.55 14.49

BRIEF-CytomX Therapeutics Q1 Revenue $14.2 Mln Vs I/B/E/S View $16.4 Mln

* CYTOMX THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Cytomx Therapeutics Provides Operational Update

* CYTOMX THERAPEUTICS ANNOUNCES FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

07 Mar 2018

BRIEF-Perceptive Advisors LLC Reports 5.6 Pct Passive Stake In CytomX Therapeutics As On Dec 8

* PERCEPTIVE ADVISORS LLC REPORTS 5.6 PERCENT PASSIVE STAKE IN CYTOMX THERAPEUTICS INC AS ON DEC 8 - SEC FILING Source text (http://bit.ly/2BGceJ2) Further company coverage:

18 Dec 2017

BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic

* CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC

28 Nov 2017

Competitors

  Price Chg
AstraZeneca plc (AZN.L) 5,443.00 +26.00
GlaxoSmithKline plc (GSK.L) 1,509.80 +13.00
Merck & Co., Inc. (MRK.N) $58.81 +0.24
Novartis AG (NOVN.S) CHF76.60 -0.40
Pfizer Inc. (PFE.N) $35.89 +0.09
Roche Holding Ltd. (ROG.S) CHF224.80 +0.25
Roche Holding Ltd. (RO.S) CHF229.40 +0.20
Sanofi SA (SASY.PA) €66.30 +0.12
ImmunoGen, Inc. (IMGN.OQ) $10.26 -0.01
Seattle Genetics, Inc. (SGEN.OQ) $55.43 +0.04

Earnings vs. Estimates